CCR4 expression in rare subtypes of cutaneous T-cell lymphomas (CTCL)a non-interventional restrospective multicenter study

• Conditions: ORPHA:178528; ORPHA:86884; ORPHA:178522; ORPHA:178533; ORPHA:86885; C84.5; C84.0; C86.3; Mycosis fungoides; C84.8

• Registration Number: DRKS00034511
• Lead Sponsor: Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Berlin, Germany

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Main group:

Adult patients with rare CTCL subtypes for whom adequate and diagnostic FFPE tumor material is available.

Control group:
- Patients with mycosis fungoides and Sézary syndrome
- Patients with inflammatory skin diseases

Exclusion Criteria

Main group:
-Patients with mycosis fungoides (MF) and Sézary syndrome (SS)
-Patients with non-validated diagnosis

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- Primary endpoint: overall survival of patients with different CCR4 expression levels

Secondary Outcome Measures

Name	Time	Method
-Secondary endpoint: time to next treatment in patients with different CCR4 expression levels